a is 0, 1 or 2; and

m and n are independently of one another 1 or 2;

and their pharmaceutically acceptable salts and prodrugs thereof.

In one embodiment, there is provided a compound that is:

1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-methylpiperazin-1-yl)benzoate;

5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-methylpiperazin-1-yl)benzoate;

5-Cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-methylpiperazin-1-yl)benzoate;

N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)benzamid;

N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide;

N-[5-Cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-Cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide;

N-[1-[4-(2,2-Difluoroethoxy)phenylsulfonyl]-3-(2-ethoxypyridin-3-yl)-5-iodo-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;

1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[4-(4-methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;

1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-(4-piperazin-1-yl-benzylamino)-1,3-dihydroindol-2-one as acetic acid salt;

5-Chloro-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-1,3-dihydroindol-2-one;

5-Chloro-3-(2-ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;

6-Chloro-3-(2-ethoxypyridin-3-yl)-5-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;

5,6-Difluoro-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;

3-(2-Ethoxypyridin-3-yl)-5-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;

3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;

1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;

3-(2-Ethoxypyridin-3-yl)-1-(4-methoxy-2-trifluoromethoxyphenylsulfonyl)-3-[4-(4-

methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-1-(4-trifluoromethoxyphenylsulfonyl)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-1-[4-(2,2,2-trifluoroethoxy)phenylsulfonyl]-2,3-dihydro-1H-indole-5-carbonitrile;
1-[4-(2,2-Difluoroethoxy)phenylsulfonyl]-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-[4-(2-fluoroethoxy)phenylsulfonyl]-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Difluoromethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(2-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(3-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Chlorophenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-Phenylsulfonyl-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Cyanophenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
(S)-3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)benzylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)benzylamino]-6-fluoro-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-[4-(2,2-Difluoroethoxy)phenylsulfonyl]-3-(2-ethoxypyridin-3-yl)-6-fluoro-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxyphenyl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[3-(4-

methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxy-2-trifluoromethoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(2-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(2-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[2-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[2-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(2-methoxyphenylsulfonyl)-3-[2-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-phenylamino]-5-iodo-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[4-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-phenylamino]-1,3-dihydroindol-2-one;
5-Chloro-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
5-Chloro-3-(2-ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
6-Chloro-3-(2-ethoxypyridin-3-yl)-5-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5,6-difluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)phenylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)phenylamino]-1-(2-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-

methylpiperazin-1-yl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[3-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[3-(4-methylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(4-Azetidin-3-ylphenylamino)-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(1-ethylazetidin-3-yl)-phenylamino]-5-iodo-1,3-dihydroindol-2-one;
3-(4-Azetidin-3-ylphenylamino)-3-(2-ethoxypyridin-3-yl)-5-iodo-1-(4-methoxy-phenylsulfonyl)-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-3-[4-(1-ethylazetidin-3-yl)phenylamino]-5-iodo-1-(4-methoxy-phenylsulfonyl)-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[6-(4-methylpiperazin-1-yl)pyridin-3-ylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[6-(4-methylpiperazin-1-yl)-pyridin-3-ylamino]-1,3-dihydroindol-2-one;
1-Phenylsulfonyl-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[6-(4-methylpiperazin-1-yl)pyridin-3-ylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-carbonyl)phenylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[4-(4-methylpiperazin-1-carbonyl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-carbonyl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-carbonyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-ylmethyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-ylmethyl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-(2,2-Difluoroethoxy)pyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Methoxyphenylsulfonyl)-3-(2-(2,2,2-trifluoroethoxy)pyridin-3-yl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-(2,2-Difluoroethoxy)phenyl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-[4-(4-Ethylpiperazin-1-yl)phenylamino]-1-(4-methoxyphenylsulfonyl)-3-(2-(2,2-difluoroethoxy)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-[4-(4-Ethylpiperazin-1-yl)phenylamino]-1-(4-methoxyphenylsulfonyl)-3-(2-(2,2,2-

trifluoroethoxy)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-(2,2-Difluoroethoxy)phenyl)-3-[4-(4-ethylpiperazin-1-yl)phenylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-3-(2-(trifluoromethoxy)phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-3-(2-(trifluoromethoxy)phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;

or a pharmaceutically acceptable salt thereof.


In one embodiment, there is provided a compound that is

3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
(S)-3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)benzylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-ylmethyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;

or a pharmaceutically acceptable salt thereof.

In one embodiment, there is provided a compound of the formula XVIII

5e



(XVIII)

in which R^1, R^2, R^3, R^5, R^6, R^7, R^8, X^1, X^4 and A are as defined herein, and

R^{12} is halogen, CN, OR^a or NR^bR^c, in which

R^a is H, C_1-C_4-alkyl, phenyl or benzyl; and

R^b and R^c are independently of one another H, C_1-C_4-alkyl, C_1-C_4-alkoxy, phenyl or benzyl.

In one embodiment, there is provided the use of a compound as defined herein or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasopressin-dependent diseases.

In one embodiment, there is provided the use of a compound as defined herein or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from diabetes, insulin resistance, nocturnal enuresis, incontinence, diseases in which impairments of blood clotting occur, hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, impairments of the renal system, edemas,

renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, impairments of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurring during chemotherapy, travel sickness, affective disorders, anxiety disorders, stress-dependent anxiety disorders, memory impairments, Alzheimer's disease, psychoses, psychotic disorders; Cushing's syndrome and other stress-dependent diseases, sleep disorders, depressive disorders, vasomotor symptoms, thermoregulatory dysfunctions, drug or pharmaceutical dependencies; stress caused by withdrawal of one or more factors mediating the dependence; stress-induced relapses into drug or pharmaceutical dependencies, schizophrenia and psychosis;

and/or for delaying micturition.

Accordingly, the present invention relates to compounds of the formula I (also "compounds I" hereinafter) and the pharmaceutically acceptable salts of the compounds I and the prodrugs of the compounds I.

The pharmaceutically acceptable salts of compounds of the formula I, which are also referred to as physiologically tolerated salts, are ordinarily obtainable by reacting the free base of the compounds I of the invention (i.e. of the compounds I according to structural formula I) with suitable acids. Examples of suitable acids are listed in "Fortschritte der Arzneimittelforschung", 1966, Birkhäuser Verlag, vol.10, pp. 224-285. These include for example hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid and fumaric acid.

The term "prodrugs" means compounds which are metabolized in vivo to the compounds I of the invention. Typical examples of prodrugs are described in C.G. Wermeth (editor): The Practice of Medicinal Chemistry, Academic Press, San Diego, 1996, pages 671-715. These include for example phosphates, carbamates, amino acids, esters, amides, peptides, ureas and the like. Suitable prodrugs in the present case may be for example compounds I in which the outer nitrogen atom of the outer nitrogen-containing ring forms an amide/peptide linkage by this nitrogen atom being substituted by a C_1-C_4-alkylcarbonyl group, e.g. by acetyl, propionyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl or tert-butylcarbonyl (pivaloyl), by benzoyl, or by an amino acid residue linked via CO, e.g. glycine, alanine, serine, phenylalanine and the like linked via CO, in the position of the radical R^4. Further suitable prodrugs are alkylcarbonyloxyalkyl carbamates in which the outer nitrogen atom of the outer nitrogen-containing ring has in the position of the radical R^4 a group of the formula -C(=O)-O-CHR^a-O-C(=O)-R^b in which R^a and R^b are independently of one another C_1-C_4-alkyl. Such carbamates are described for example in J. Alexander, R. Cargill, S. R. Michelson, H. Schwam, J. Medicinal Chem. 1988, 31(2), 318-322. These groups can then be eliminated under metabolic conditions and result in compounds I in which R^4 is H.